Christiana Stamoulis - Net Worth and Insider Trading

Christiana Stamoulis Net Worth

The estimated net worth of Christiana Stamoulis is at least $17 Million dollars as of 2023-09-26. Christiana Stamoulis is the SVP, Corp Strategy & Bus Devlp of Vertex Pharmaceuticals Inc and owns about 41,651 shares of Vertex Pharmaceuticals Inc (VRTX) stock worth over $15 Million. Christiana Stamoulis is also the Director of Hologic Inc and owns about 39,392 shares of Hologic Inc (HOLX) stock worth over $3 Million. Details can be seen in Christiana Stamoulis's Latest Holdings Summary section.

Transaction Summary of Christiana Stamoulis


Christiana Stamoulis Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Christiana Stamoulis owns 4 companies in total, including Incyte Corp (INCY) , Hologic Inc (HOLX) , and Cogent Biosciences Inc (COGT) among others .

Click here to see the complete history of Christiana Stamoulis’s form 4 insider trades.

Insider Ownership Summary of Christiana Stamoulis

Ticker Comapny Transaction Date Type of Owner
INCY Incyte Corp 2019-02-11 EVP & Chief Financial Officer
HOLX Hologic Inc 2011-11-01 director
COGT Cogent Biosciences Inc 2018-03-28 President & C.F.O.
VRTX Vertex Pharmaceuticals Inc 2010-10-06 SVP & Corp Strategy & Bus Devlp

Christiana Stamoulis Latest Holdings Summary

Christiana Stamoulis currently owns a total of 2 stocks. Among these stocks, Christiana Stamoulis owns 41,651 shares of Vertex Pharmaceuticals Inc (VRTX) as of July 15, 2013, with a value of $15 Million and a weighting of 84.09%. Christiana Stamoulis also owns 39,392 shares of Hologic Inc (HOLX) as of November 4, 2020, with a value of $3 Million and a weighting of 15.91%.

Latest Holdings of Christiana Stamoulis

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
VRTX Vertex Pharmaceuticals Inc 2013-07-15 41,651 350.67 14,605,756
HOLX Hologic Inc 2020-11-04 39,392 70.13 2,762,561

Holding Weightings of Christiana Stamoulis

Christiana Stamoulis Form 4 Trading Tracker

According to the SEC Form 4 filings, Christiana Stamoulis has made a total of 0 transactions in Vertex Pharmaceuticals Inc (VRTX) over the past 5 years. The most-recent trade in Vertex Pharmaceuticals Inc is the sale of 1,125 shares on July 15, 2013, which brought Christiana Stamoulis around $97,144.

According to the SEC Form 4 filings, Christiana Stamoulis has made a total of 4 transactions in Hologic Inc (HOLX) over the past 5 years, including 0 buys and 4 sells. The most-recent trade in Hologic Inc is the sale of 11,146 shares on November 4, 2020, which brought Christiana Stamoulis around $824,804.

Insider Trading History of Christiana Stamoulis

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Christiana Stamoulis Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Christiana Stamoulis Ownership Network

Ownership Network List of Christiana Stamoulis

No Data

Ownership Network Relation of Christiana Stamoulis

Christiana Stamoulis Owned Company Details

What does Incyte Corp do?

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Who are the key executives at Incyte Corp?

Christiana Stamoulis is the EVP & Chief Financial Officer of Incyte Corp. Other key executives at Incyte Corp include President & R&D Pablo J Cagnoni , Principal Accounting Officer Thomas Tray , and EVP & General Manager & Europe Jonathan Elliott Dickinson .

Incyte Corp (INCY) Insider Trades Summary

Over the past 18 months, Christiana Stamoulis made no insider transaction in Incyte Corp (INCY). Other recent insider transactions involving Incyte Corp (INCY) include a net sale of 30,111 shares made by Vijay K Iyengar , a net sale of 49,910 shares made by Steven H Stein , and a net sale of 46,866 shares made by Barry P Flannelly .

In summary, during the past 3 months, insiders sold 29,960 shares of Incyte Corp (INCY) in total and bought 0 shares, with a net sale of 29,960 shares. During the past 18 months, 200,566 shares of Incyte Corp (INCY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 200,566 shares.

Incyte Corp (INCY)'s detailed insider trading history can be found in Insider Trading Tracker table.


Incyte Corp Insider Transactions

No Available Data

Christiana Stamoulis Mailing Address

Above is the net worth, insider trading, and ownership report for Christiana Stamoulis. You might contact Christiana Stamoulis via mailing address: C/o Vertex Pharmaceuticals Incorporated, 130 Waverly St, Cambridge Ma 02139.

Discussions on Christiana Stamoulis

No discussions yet.